Aicuris press release
Aicuris announced superior efficacy results from a subgroup analysis of its pivotal Phase 3 trial (PRIOH-1) evaluating pritelivir vs. investigator’s choice in people living with HIV with refractory herpes simplex virus (HSV) infection. The results were presented as a late-breaking oral presentation at CROI 2026.
In the subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete lesion healing compared with 20% receiving investigator’s choice therapy with an adjusted treatment difference of 37% (p = 0.027) in people living with HIV with refractory HSV
infections.
People living with HIV face a higher risk of severe, refractory HSV infections due to weakened immunity. HSV-2 also increases HIV acquisition risk, and co-infection can cause aggressive, prolonged, painful lesions and may accelerate HIV progression. Repeated antiviral use for treatment of HSV recurrence increases the risk of resistance, underscoring the urgent need for more effective HSV therapies for this vulnerable population.
Read the full press release here.
SEE ALSO:
Source : Aicuris
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.